Study S002001

Recombinant Zoster Vaccine (Shingrix) and GLP-1 Receptor Agonist for the Preservation of Beta-Cell Function in Adults With Recent-Onset Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.

ClinicalTrials.gov record

Registration

Registration: NCT07614412
Acronym: SHIELD-T1D
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 240
Start: 2027-01-01
Primary completion: 2028-01-31
Lead sponsor: Ministry of Health, Saudi Arabia
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG:Recombinant Zoster Vaccine (Shingrix; RZV); DRUG:Semaglutide (Ozempic®); DRUG:Placebo (saline injection)
Results posted: FALSE

Registered primary outcomes

Change in 2-hour stimulated C-peptide Area Under the Curve (AUC) during a Mixed Meal Tolerance Test (MMTT) [Baseline and 12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.